Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Building on the principals that the adoptive transfer of T cells can lead to the regression of established tumors in humans, investigators are now further manipulating these cells using genetic engineering. Two decades of human gene transfer experiments have resulted in the translation of laboratory technology into robust clinical applications. The purpose of this review is to give the reader an introduction to the 2 major approaches being developed to redirect effector T-cell specificity. Primary human T cells can be engineered to express exogenous T-cell receptors or chimeric antigen receptors directed against multiple human tumor antigens. Initial clinical trial results have demonstrated that both T-cell receptor- and chimeric antigen receptor-engineered T cells can be administered to cancer patients and mediate tumor regression.
Morgan
Richard A
RA
Surgery Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA. rmorgan@mail.nih.gov
Dudley
Mark E
ME
Rosenberg
Steven A
SA
D000818:Animals; D018984:Epitopes, T-Lymphocyte / Q000235:genetics* / Q000276:immunology*; D018014:Gene Transfer Techniques; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000502:physiology*
D018984:Epitopes, T-Lymphocyte